144 related articles for article (PubMed ID: 22032293)
1. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma.
Ponziani F; Ojetti V; Tortora A; Di Maurizio L; Purchiaroni F; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1535-46. PubMed ID: 22032293
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitor for the treatment of hepatocellular carcinoma.
Kudo M
Dig Dis; 2011; 29(3):310-5. PubMed ID: 21829022
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
Duvoux C; Toso C
Transplant Rev (Orlando); 2015 Jul; 29(3):168-74. PubMed ID: 26071984
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
7. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
9. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.
Matter MS; Decaens T; Andersen JB; Thorgeirsson SS
J Hepatol; 2014 Apr; 60(4):855-65. PubMed ID: 24308993
[TBL] [Abstract][Full Text] [Related]
10. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
11. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
[TBL] [Abstract][Full Text] [Related]
12. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors.
Capdevila J; Salazar R; Halperín I; Abad A; Yao JC
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():27-34. PubMed ID: 21311955
[TBL] [Abstract][Full Text] [Related]
13. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
14. The mTOR protein as a target in thyroid cancer.
Souza EC; Ferreira AC; Carvalho DP
Expert Opin Ther Targets; 2011 Sep; 15(9):1099-112. PubMed ID: 21702716
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
16. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
[TBL] [Abstract][Full Text] [Related]
18. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
Welker MW; Bechstein WO; Zeuzem S; Trojan J
Transpl Int; 2013 Feb; 26(2):109-18. PubMed ID: 22994652
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
[TBL] [Abstract][Full Text] [Related]
20. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
Li SZ; Xu F; Sun CQ; Xu P
Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]